oltipraz Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Oltipraz is an organosulfur compound belonging to the dithiolethione class. It acts as a schistosomicide and has been shown in rodent models to inhibit the formation of cancers in the bladder, blood, colon, kidney, liver, lung, pancreas, stomach, and trachea, skin, and mammary tissue. Clinical trials of oltipraz have failed to demonstrate efficacy and have shown significant side effects, including neurotoxicity and gastrointestinal toxicity. Oltipraz has also been shown to generate superoxide radicals, which can be toxic.   Wikipedia

Chemistry

  • SMILES: Cc1c(-c2cnccn2)ssc1=S
  • InChIKey: CKNAQFVBEHDJQV-UHFFFAOYSA-N
  • Mol. Mass: 226.35
  • ALogP: 3.3
  • ChEMBL Molecule:
    oltipraz  
More Chemistry

Pharmacology

Alternative names

35 972 r.p. | 3h-1,2-dithiole-3-thione, 4-methyl-5-pyrazinyl- | 4-methyl-5-pyrazinyl-3h-1,2-dithiole-3-thione | 4-methyl-pdt | 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione | oltipraz | rp 35972

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Liver Cirrhosis (Phase 2)

Lung Neoplasms (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue